PROX1 and breast cancer: Statistical analysis also showed that the expression of PROX1 was the lowest in Luminal A subtype breast cancer patients without lymph node metastasis, while the expression was highest in triple-negative breast cancer patients with lymph node metastasis (Fig. 1G).